The best of SABSC 2017
The San Antonio Breast Cancer Symposium, hosted in Texas, USA, came to a successful conclusion on the 9th December. Just in case you missed it, here is a summary of what we thought were the key highlights of the scientific event.
The date for next year’s symposium is already in the diary, so be sure to save the date for the 4–8th 2018.
Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-low Breast Cancer
Research led by Louis Fehrenbacher, MD, medical director of Kaiser Permanente Oncology Clinical Trials and an oncologist with the Kaiser Permanente Vallejo Medical Center, California found current guidelines guidelines for defining HER2-positive status remain valid... read more
Risk of breast cancer recurrence and death reduced
The results of an EBCTCG meta-analysis study, which were presented at the San Antonio Breast Cancer Symposium 2017 this week, revealed that increasing the dose intensity of chemotherapy shortening the intervals between cycles or replacing concurrent administration with sequential administration of the drugs lessened the risk of early-stage breast cancer recurrence and death... read more
MONALEESA-7 trial demonstrates significant outcomes in breast cancer
Phase III clinical trial data presented this week at the 2017 San Antonio Breast Cancer Symposium, Texas has shown that adding the CDK4/6 inhibitor ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor–positive (HR-positive), HER2-negative breast cancer... read more
Hope for patients with Trastuzumab-resistant breast cancer
Patients whose breast cancer tumours were positive for a biomarker for pembrolizumab showed signs of promise on a combination of pembrolizumab (Keytruda) and trastuzumab (tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer)... read more
Breast cancer patients undergo years of unnecessary treatment
Postmenopausal women with hormone-receptor positive (HR-positive) breast cancer who took the aromatase inhibitor anastrozole for two years after an initial five years of adjuvant endocrine therapy experienced an equal benefit to those who took the drug for five additional years... read more
Phase III trial data support current standard 12-month adjuvant Trastuzumab for HER2-positive breast cancer
Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment... read more
Call to update guidelines on fertility in Breast Cancer following successful trial
Data presented today at the 2017 San Antonio Breast Cancer Symposium, suggested a high level of evidence that treatment with a gonadotropin-releasing hormone analog (GnRHa) could safely and effectively protect ovarian function and potentially preserve fertility in premenopausal women receiving chemotherapy for early-stage breast cancer... read more
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
